161 related articles for article (PubMed ID: 7587865)
1. Lipoprotein(a), apolipoprotein(a) polymorphism, and insulin treatment in type II diabetic patients.
Buscaglia P; Gazzaruso C; Garzaniti A; Bonetti G; Fratino P; Geroldi D
Diabetes Care; 1995 Aug; 18(8):1202-3. PubMed ID: 7587865
[No Abstract] [Full Text] [Related]
2. Serum lipoprotein(a) is increased in hypertensive NIDDM patients.
Hancu N; Netea MG; Iancu S
Diabetes Care; 1995 Jun; 18(6):879-80. PubMed ID: 7555518
[No Abstract] [Full Text] [Related]
3. [Importance of the determination of fructosamine in monitoring diabetic patients].
Vinci VS; Masotti G; Citro G; De Marca S; Quaglia C; Galasso R
Medicina (Firenze); 1990; 10(1):25-7. PubMed ID: 2381275
[TBL] [Abstract][Full Text] [Related]
4. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.
Hirata K; Saku K; Jimi S; Kikuchi S; Hamaguchi H; Arakawa K
Diabetologia; 1995 Dec; 38(12):1434-42. PubMed ID: 8786017
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.
Nielsen FS; Voldsgaard AI; Gall MA; Rossing P; Hommel E; Andersen P; Dyerberg J; Parving HH
Diabetologia; 1993 May; 36(5):438-44. PubMed ID: 8314449
[TBL] [Abstract][Full Text] [Related]
6. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins.
Vaverková H; Chlup R; Ficker L; Novotny D; Bartek J
Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():74-7. PubMed ID: 9288551
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein lipids and apolipoproteins (AI, AII, B, CII, CIII) in type 1 and type 2 diabetes mellitus in young Kuwaiti women.
al-Muhtaseb N; al-Yusef AR; Bajaj JS
Diabet Med; 1991 Oct; 8(8):732-7. PubMed ID: 1838064
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) as a coronary risk factor in Japanese patients with Type II (non-insulin-dependent) diabetes mellitus. Relation with apolipoprotein(a) phenotypes.
Murakami K; Ishibashi S; Yoshida Y; Yamada N; Akanuma Y
Diabetologia; 1998 Nov; 41(11):1397-8. PubMed ID: 9833951
[No Abstract] [Full Text] [Related]
9. Comparison of different insulin regimens in elderly patients with NIDDM.
Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a), apolipoprotein(a) phenotypes, and nephropathy in NIDDM patients.
Akita H; Chiba H; Noritake M; Katsura Y; Udo Y; Shibuya H; Hui SP; Takahashi Y; Nagasaka H
Diabetes Care; 1996 Sep; 19(9):1036-7. PubMed ID: 8875111
[No Abstract] [Full Text] [Related]
12. The use of low glycaemic index foods improves metabolic control of diabetic patients over five weeks.
Fontvieille AM; Rizkalla SW; Penfornis A; Acosta M; Bornet FR; Slama G
Diabet Med; 1992 Jun; 9(5):444-50. PubMed ID: 1611832
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein subfraction composition in non-obese newly diagnosed non-insulin dependent diabetes after treatment with diet and glibenclamide.
Billingham MS; Milles JJ; Bailey CJ; Hall RA
Diabetes Res; 1989 May; 11(1):13-20. PubMed ID: 2515931
[TBL] [Abstract][Full Text] [Related]
14. Vascular complications of patients in Kuwait with type 2 diabetes mellitus (NIDDM) and elevated serum lipid peroxides.
Lanham RJ; Armstrong D; Abdella N
Adv Exp Med Biol; 1994; 366():433-5. PubMed ID: 7771283
[No Abstract] [Full Text] [Related]
15. Apolipoprotein A-I, A-II, B, C-II, and C-III in children with insulin-dependent diabetes mellitus.
al Muhtaseb N; al Yousuf A; Bajaj JS
Pediatrics; 1992 May; 89(5 Pt 1):936-41. PubMed ID: 1579407
[TBL] [Abstract][Full Text] [Related]
16. [The effect of hyperlipoproteinemia on serum fructosamine].
Drexel H; Patsch JR
Wien Klin Wochenschr Suppl; 1990; 180():24-32; discussion 32-3. PubMed ID: 2321387
[TBL] [Abstract][Full Text] [Related]
17. Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus.
Császár A; Dieplinger H; Sandholzer C; Karádi I; Juhász E; Drexel H; Halmos T; Romics L; Patsch JR; Utermann G
Diabetologia; 1993 Jan; 36(1):47-51. PubMed ID: 8436252
[TBL] [Abstract][Full Text] [Related]
18. The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM.
Chan JC; Yeung VT; Leung DH; Tomlinson B; Nicholls MG; Cockram CS
Diabetes Care; 1994 Aug; 17(8):859-62. PubMed ID: 7956631
[TBL] [Abstract][Full Text] [Related]
19. Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels.
Wolffenbuttel BH; Leurs PB; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
Diabet Med; 1993 Jun; 10(5):427-30. PubMed ID: 8334821
[TBL] [Abstract][Full Text] [Related]
20. Serum lipoprotein(a) in patients with diabetes mellitus.
Heller FR; Jamart J; Honore P; Derue G; Novik V; Galanti L; Parfonry A; Hondekijn JC; Buysschaert M
Diabetes Care; 1993 May; 16(5):819-23. PubMed ID: 8495624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
